Therapy Name | LY411575 + Paclitaxel |
Therapy Description |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY411575 | Gamma secretase inhibitor 12 | LY411575 is a gamma secretase inhibitor, which blocks Notch cleavage and activation, and may inhibit angiogenesis and tumor growth (PMID: 14709552). | ||
Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 11 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | ERBB2 neg ERBB2 pos | Her2-receptor negative breast cancer | sensitive | LY411575 + Paclitaxel | Preclinical | Actionable | In a preclinical study, circulating tumor cells (CTC) from patients with ERBB2 (HER2)-negative breast cancer were demonstrated to contain both ERBB2 (HER2)-positive and ERBB2 (HER2)-negative subpopulations, and the combination of LY411575 and Taxol (paclitaxel) resulted in increased tumor growth inhibition in CTC-derived xenograft models compared to either agent alone (PMID: 27556950). | 27556950 |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|